SCHEMBL15218113

SCHEMBL15218113

CN(CCO)c1ccc(/C=C/C(=O)c2ccc(NC(=O)CCCl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.54
KMT2A Q03164 5/20 0.54
LMNA P02545 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
TUBB4A P04350 3/20 0.49
TUBB P07437 3/20 0.49
TUBA3C P0DPH7 3/20 0.49
TUBA1B P68363 3/20 0.49
TUBA4A P68366 3/20 0.49
TUBB4B P68371 3/20 0.49
TUBB3 Q13509 3/20 0.49
TUBB2A Q13885 3/20 0.49
TUBB8 Q3ZCM7 3/20 0.49
TUBA3E Q6PEY2 3/20 0.49
TUBA1A Q71U36 3/20 0.49
TUBA1C Q9BQE3 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25196954 0.93 MAPT (0.64) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15218195 0.92 TUBB4A (0.56) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15216644 0.92 MAPT (0.60) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL25235979 0.89 MAPT (0.52) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15216645 0.89 MAPT (0.52) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL25207647 0.89 KMT2A (0.53) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15218427 0.88 MAPT (0.50) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15218081 0.88 MAPT (0.50) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15218415 0.87 TUBB4A (0.69) MAPTKMT2ALMNACYP1A2CYP3A4
SCHEMBL15218332 0.87 TUBB4A (0.57) MAPTKMT2ALMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-8871976-B2 Chalcone structure fluorescence dye for embryonic stem cell probe NATIONAL UNIVERSITY OF SINGAPORE (SG) 2014-10-28 US disclosed
US-20130224790-A1 Chalcone Structure Fluorescence Dye For Embryonic Stem Cell Probe AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885LMNA 1180/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885LMNA 1817/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885LMNA 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.